Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma

NCT01334515 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01334515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01334515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
September 30, 2019
Enrollment
52 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent neuroblastoma